Le-Petross Huong T, Lim Bora
Department of Diagnostic Imaging, University of Texas MD Anderson Cancer Center, 1155 Pressler Street, Houston, TX 77030, USA.
Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, 1155 Pressler Street, Houston, TX 77030, USA.
Magn Reson Imaging Clin N Am. 2018 May;26(2):207-220. doi: 10.1016/j.mric.2017.12.011. Epub 2018 Mar 2.
Neoadjuvant chemotherapy (NAC) has become an important treatment approach for stage II/III breast cancers to downsize tumor and enable breast-conserving surgery for patients that may otherwise undergo mastectomy. MR imaging has the potential to identify early response or disease progression, enabling potential modification to NAC regimens. Detection of size and morphologic changes is better appreciated with MR imaging than other modalities and is different between molecular subtypes of breast cancer. The combination of DCE-MR imaging and DWI provides the highest sensitivity and specificity. Other new modalities such as FDG PET/MR imaging and molecular breast imaging are still undergoing research.
新辅助化疗(NAC)已成为II/III期乳腺癌的一种重要治疗方法,可缩小肿瘤大小,使原本可能需要接受乳房切除术的患者能够进行保乳手术。磁共振成像(MR成像)有潜力识别早期反应或疾病进展,从而有可能调整NAC方案。与其他检查方式相比,MR成像在检测肿瘤大小和形态变化方面更具优势,且不同分子亚型的乳腺癌在这方面存在差异。动态对比增强磁共振成像(DCE-MR成像)和扩散加权成像(DWI)相结合可提供最高的灵敏度和特异性。其他新的检查方式,如氟代脱氧葡萄糖正电子发射断层显像/磁共振成像(FDG PET/MR成像)和分子乳腺成像仍在研究中。